Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Are Selected for Spectra Luminaires by European Lighting Manufacturer LED Luks
Seoul Semiconductor, a global innovator of LED products and technology, announces that its SunLike Series LEDs, which implement light closest to the spectrum of natural sunlight, have been adopted for the Spectra luminaires of LED Luks, a specialty lighting company based in Slovenia.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180309005197/en/
The Spectra luminaires of LED Luks equipped with SunLike LED technology (left) shows colors and textures accurately. (Photo: Business Wire)
LED Luks, a manufacturer of technical and architectural LED luminaires in Slovenia, has chosen SunLike Series LEDs for its Plain Spectra and Kyra Spectra pendant luminaires, featuring up to 125 - 130lm/W luminous efficacy. SunLike Series LEDs can be used as direct/indirect lighting for adjusted color temperature between 2700K (warm white) and 5000K (cool white). The Plain Spectra luminaires were designed by the renowned Swedish designer Kai Piippo.
Matija Klinkon, CEO of LED Luks, said “Besides their aesthetic design, Spectra luminaires feature light that best represents the natural color and texture of objects. By adopting SunLike as the light source, Spectra luminaires are able to produce light closest to the spectrum of natural sunlight, diminishing the negative effects of artificial light sources. Natural spectrum lighting is believed to have a positive influence on human biorhythms and contribute to a better and healthier environment. We anticipate that Spectra luminaires will further expand from the European market to the world.”
According to Caleb Won, executive VP of global marketing at Seoul Semiconductor, “Brightness and price are no longer the main factors of competition in global lighting market. Now, the lighting market is entering the human centric era, in which lighting systems are evaluated for the benefit of human health, Seoul Semiconductor is pleased to release our SunLike Series LEDs in cooperation with LED Luks in Europe, and we intend to expand the supply of SunLike lighting products to the world, opening the era of natural spectrum sunlight lighting era.”
About SPECTRA
Luminaires under the Spectra brand accurately represent the color and texture of objects. With an ideal color reproduction (CRI 97), they appear as they would under natural sunlight. Available in Plain Spectra and Kyra Spectra.
About TRI-R technology
TRI-R is a registered trademark of Toshiba Material Co., Ltd. It is a natural light LED light source technology that reproduces the spectrum of natural sunlight, developed by the concept and spectrum technology of natural light.
About LED Luks
LED Luks is a young and dynamic company, designing, developing and producing state-of-the-art LED luminaires with superior functionality, up-to-date efficiency, outstanding quality and appealing design. It is our belief that only the best components and latest technology satisfy our clients’ needs and guarantee long lasting quality as well as a steady growth. We produce our own PCBs and work closely with many testing institutes in order to ensure reliability. Listening to clients’ needs and inspired by the dialog with our partners, we create our standard product lines, as well as special custom made solutions.
For more information about LED Luks, please visit http://www.ledluks.com
About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series – the world’s smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC.
For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com
# Trademarks
WICOP and Acrich are trademarks of Seoul Semiconductor Co., Ltd.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180309005197/en/
Contact information
Europe
Seoul Semiconductor Europe GmbH
Ariane Heim
Tel:
+49-(0)89-450-3690-0
Email: press.eu@seoulsemicon.com
or
North
America
Seoul Semiconductor Inc.
Andrew Smith
Tel: +1
(901) 831-6614
Email: andrew.smith@seoulsemicon.com
or
Asia
Seoul
Semiconductor Co., Ltd
Jake Jung
Tel: +82 070.4391.8270
Email:
pr@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom